MCL1 and breast carcinoma: These results indicate that the combination of PI3Kβ/AKT inhibitors with a Mcl-1 inhibitor could be an effective therapeutic strategy to enhance treatment response and overcome mTORC1-driven acquired resistance to PI3K pathway inhibitors in PTEN-deficient breast cancer.